Business Context and Reporting Period
This Form 8-K Current Report was filed by Imprimis Pharmaceuticals, Inc. (noted as Harrow, Inc. in metadata) on April 28, 2017. The report details the entry into a Material Definitive Agreement with SightLife Surgical, Inc. regarding the sales and marketing of the Company's autologous serum tears compound formulation.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period. The financial implications are limited to the terms of the new agreement:
- Commission Structure: 10% of annual net sales for the Products.
- Equity Milestones: Payments in restricted common stock based on net sales thresholds ranging from $2,000,000 to $10,000,000.
Material Changes
The primary material change is the execution of the Strategic Sales & Marketing Agreement on April 28, 2017. This agreement grants SightLife exclusive United States sales and marketing representation services for the Company's autologous serum tears compound formulation. No other material changes to financial position or operations are disclosed in this specific filing.
Guidance, Outlook, and Risks
Outlook: The agreement establishes a sales framework with specific performance milestones tied to net sales targets for the Products.
Risks and Contingencies: The Company's obligation to issue restricted common stock is contingent upon achieving specific net sales thresholds. The filing notes that the summary provided is not a complete description of rights and obligations, referring investors to the full text of the agreement filed as Exhibit 10.1.
Investor Verification Checklist
- Verify the full terms of the Strategic Sales & Marketing Agreement in Exhibit 10.1.
- Confirm the current valuation of the Company's restricted common stock to assess the potential dilution from milestone payments.
- Review the Press Release issued on May 2, 2017 (Exhibit 99.1) for additional context on the partnership.
- Monitor future filings for actual net sales figures to determine if milestone thresholds are met.